United Drug delivers solid first half results

FTSE 250-listed outsourced commercialisation services provider United Drug delivered solid results for the first half of the year underpinned by growth in its US packaging division.

FTSE 250-listed outsourced commercialisation services provider United Drug delivered solid results for the first half of the year underpinned by growth in its US packaging division.

Operating profits across the group in the six months to March 31st were up 13% and revenue was up 14% to €1.02bn, from the corresponding period in 2012.

Earnings per share were 7.0% higher on the same period of 2012. Strong cash flow performance was recorded with operating cash flow of €55.8m in the period, significantly up on the €20.4m generated in the same period of 2012.

The packaging and specialty division revenue for the period was recorded at €99m, 26% higher than the same period in 2012, with operating profit growing by 25%.

Revenue for the Sales, Marketing & Medical division of €182m was 113% higher than the same period in 2012. Much of the growth came from the recently acquired Pharmexx businesses, the group said, which had lower margins than its existing business at the time of acquisition.

Revenue for the Healthcare Supply Chain division for the period of €736m was 1.0% ahead of 2012. Operating profits increased by 2.0% over the same period in 2012.

In September, the group plans to re-brand as 'UDG Healthcare', subject to shareholder approval so as to apply brand consistency within each division. The group said that an EGM notice seeking approval for the change would be circulated to shareholders in the coming weeks.

Liam FitzGerald, Chief Executive Officer of United Drug, commented: "The first half of 2013 has seen us integrate our recent acquisitions, structure our business for future growth and deliver 13% operating profit growth."

He added: "During the period, the US became our largest profit contributing region, followed closely by the UK and the rest of Europe. We continue to work hard to provide a range and quality of professional outsourcing solutions that enable our international healthcare clients to operate more effectively."

United Drug's share price was down 0.62% to 306.20p at 10:10 on Thursday.

MF

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
23 Jan 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
5 Jan 2023
Investing trends to watch out for in 2023: what analysts say
Investment strategy

Investing trends to watch out for in 2023: what analysts say

What are sensible strategies for high inflationary times? We ask analysts to find out.
22 Dec 2022

Most Popular

Council tax increases 2023 – how much more will you pay?
Tax

Council tax increases 2023 – how much more will you pay?

Your council tax bill will go up in April - we reveal the councils that have confirmed what this year’s increase will be.
23 Jan 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Wholesale gas prices are on a downward trajectory, but does this mean lower energy bills later this year?
27 Jan 2023
When will interest rates go up?
UK Economy

When will interest rates go up?

New interest rates will be announced on 2 February – we look at what to expect.
26 Jan 2023